{"id":"W2532238474","doi":"10.1111/jdv.14015","title":"The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo‐controlled trial (LIBERATE)","year":2016,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":198,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research","funders":"Cilag; Regeneron Pharmaceuticals; UCB Pharma; Medac; LEO Pharma; Eli Lilly and Company; Galderma; Biogen; Celgene; GlaxoSmithKline; Amgen; Pfizer","keywords":"Medicine; Apremilast; Placebo; Etanercept; Psoriasis; Randomized controlled trial; Dermatology; Internal medicine; Physical therapy; Psoriatic arthritis; Alternative medicine; Tumor necrosis factor alpha; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001434853,0.0003020025,0.001484702,0.0001737998,0.0002051702,0.00000825567,0.0003365813,0.0003139887,0.0000116629],"category_scores_gemma":[0.0007264992,0.0001342993,0.000144323,0.00009412207,0.00103045,0.0001005213,0.0001710745,0.0004150508,0.000005853373],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001656808,"about_ca_system_score_gemma":0.00005878749,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000005933516,"about_ca_topic_score_gemma":0.0000104615,"domain_scores_codex":[0.9929323,0.004982547,0.001385461,0.0003022863,0.00007636414,0.0003210248],"domain_scores_gemma":[0.9938475,0.004566029,0.001266674,0.0001782134,0.00007539184,0.00006616465],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9834428,0.0003282554,0.004365991,0.000008450418,0.001270893,0.00001673885,0.0007953822,0.0000191878,0.001271724,0.0001913955,0.0003997121,0.007889413],"study_design_scores_gemma":[0.9812121,0.0004777311,0.01341937,0.0002018147,0.0006571371,0.000451237,0.00007076313,0.000006991827,0.002118459,0.0003191012,0.0008971779,0.0001680982],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9919224,0.002472088,0.00004085235,0.003618724,0.0003833721,0.001176067,0.0001051676,0.000006424469,0.0002749416],"genre_scores_gemma":[0.9980257,0.001480397,0.00008330288,0.0001225282,0.00006470137,0.00001364556,0.000005859147,0.00002005171,0.0001837746],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009053383,"threshold_uncertainty_score":0.5476567,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01107462923802612,"score_gpt":0.2306057609492769,"score_spread":0.2195311317112508,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}